



**ONCO MOLECULES (Plant validation planned in this FY)**

S.No.	Product Type	Product Name	Status	Remarks
1	Onco	Palbociclib	Lab validatiob U/Process.	Tentatively in Q4
2	Onco	Carmustine	LV completed, U/PDR prep	Tentatively in Q4
3	Onco	Abriterone Acetae	Lab validation U/Process	Tentatively in Q4
4	Onco	Pazopanib Hcl	Plant validation stage-IV to	Tentatively in Q4.
5	Onco	Nilotinib HCl	Under validation	Tentatively in Q4.
6	Onco	Nintedanib	Plant validation to be start.	Tentatively in Q4.

**ONCO MOLECULES (Under Development)**

<b>S.No.</b>	<b>Product Type</b>	<b>Product Name</b>	<b>Remarks</b>
1	Onco	Cladribine	U/Optimization
2	Onco	Regorafenib	Optimization to be start.
3	Onco	Afatinib Dimaleate	Optimization completed.
7	Onco	Tofacitinib citrate	U/Optimization.



**NON-ONCO MOLECULES (Plant validation planned in this FY)**

<b>S.No.</b>	<b>Product Type</b>	<b>Product Name</b>	<b>Status</b>	<b>Remarks</b>
1	Non-Onco	UDCA	Plant Validation U/Process.	Tentatively Q3.
2	Non-Onco	Abacavir Sulfate	Plant Validation U/Process.	Tentatively in Q4.
3	Non-Onco	Levetiracetam	Plant validation to be start.	Tentatively Q4.
4	Non-Onco	Molupinavir	Validation completed	
6	Non-Onco	Eltrombopag olamine	Plant validation to be start.	Tentatively Q4.
7	Non-Onco	Montelukast sodium	U/ Lab validation.	Tentatively Q4.
8	Non-Onco	Oxcarbazepine	ation will complete by this m	Tentatively Q4.
9	Non-Onco	NOR UDCA	Plant validation to be start.	Tentatively Q4.
10	Non-Onco	Dolutegravir	U/ Lab validation.	Tentatively Q4.

**NON-ONCO MOLECULES (Under Development)**

<b>S.No.</b>	<b>Product Type</b>	<b>Product Name</b>	<b>Remarks</b>
1	Non-Onco	Carbamazepine	U/Optimization
2	Non-Onco	Clopidogrel	U/Optimization
3	Non-Onco	Dextromethorphan hydrobromide	U/ Optimization
4	Non-Onco	Duloxetine HCl	U/ Feasability study
5	Non-Onco	Echothiophate Iodide	U/ Optimization
6	Non-Onco	Losartan Potassium	U/ Fesability.
8	Non-Onco	Valacyclovir HCl	U/Optimization
9	Non-Onco	Valsartan	U/Optimization